相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - Long-term results of trial ALL-REZ BFM P95/96
Cornelia Eckert et al.
EUROPEAN JOURNAL OF CANCER (2013)
Rituximab Maintenance Compared With Observation After Brief First-Line R-FND Chemoimmunotherapy With Rituximab Consolidation in Patients Age Older Than 60 Years With Advanced Follicular Lymphoma: A Phase III Randomized Study by the Fondazione Italiana Linfomi
Umberto Vitolo et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma
F. Morschhauser et al.
ANNALS OF ONCOLOGY (2012)
Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia
Malek Faham et al.
BLOOD (2012)
Impact of [18F]Fluorodeoxyglucose Positron Emission Tomography Response Evaluation in Patients With High-Tumor Burden Follicular Lymphoma Treated With Immunochemotherapy: A Prospective Study From the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS
Jehan Dupuis et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Follicular lymphoma: 2011 update on diagnosis and management
Arnold Freedman
AMERICAN JOURNAL OF HEMATOLOGY (2011)
Positron Emission Tomography-Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset of PRIMA Trial Participants
Judith Trotman et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
RADIATION DOSE MANAGEMENT IN CT, SPECT/CT AND PET/CT TECHNIQUES
Soren Mattsson et al.
RADIATION PROTECTION DOSIMETRY (2011)
BCL-2/IgH Polymerase Chain Reaction Status at the End of Induction Treatment Is Not Predictive for Progression-Free Survival in Relapsed/Resistant Follicular Lymphoma: Results of a Prospective Randomized EORTC 20981 Phase III Intergroup Study
Marinus H. J. van Oers et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Quantitative PCR Analysis for Bcl-2/IgH in a Phase III Study of Yttrium-90 Ibritumomab Tiuxetan As Consolidation of First Remission in Patients With Follicular Lymphoma
Lindsey Goff et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Presence of t(14;18) positive cells in blood and bone marrow does not predict outcome in follicular lymphoma
E. Paszkiewicz-Kozik et al.
MEDICAL ONCOLOGY (2009)
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage
Marco Ladetto et al.
BLOOD (2008)
Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab:: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients
Carsten Hirt et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations
Sebastian Boettcher et al.
HAEMATOLOGICA (2008)
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders
Andy C. Rawstron et al.
HAEMATOLOGICA (2008)
Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission
Jennifer R. Brown et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Novel multi-parameter flow cytometry sensitively detects phenotypically distinct plasma cell subsets in plasma cell proliferative disorders
W. G. Morice et al.
LEUKEMIA (2007)
One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells:: Is the end of molecular monitoring near?
Christina Schmitt et al.
LEUKEMIA RESEARCH (2006)
Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma
Marco Ladetto et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2006)
Cells carrying nonlymphoma-associated bcl-2/IgH rearrangements (NLABR) are phenotypically related to follicular lymphoma and can establish as long-term persisting clonal populations
Marco Ladetto et al.
EXPERIMENTAL HEMATOLOGY (2006)
Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program:: updated results of the multicenter consecutive GITMO trial
M. Ladetto et al.
LEUKEMIA (2006)
Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at the University of Texas M.D. Anderson Cancer Center
Q Liu et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
New treatment options have changed the survival of patients with follicular lymphoma
RI Fisher et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma
A Rambaldi et al.
BLOOD (2005)
Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: Evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes
P Corradini et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly X 4 schedule
M Ghielmini et al.
BLOOD (2004)
Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone
M Ladetto et al.
EXPERIMENTAL HEMATOLOGY (2003)
PCR-detectable nonneoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis but rare in subjects treated with chemotherapy
M Ladetto et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO)
M Ladetto et al.
BLOOD (2002)
Real-time polymerase chain reaction in multiple myeloma:: Quantitative analysis of tumor contamination of stem cell harvests
M Ladetto et al.
EXPERIMENTAL HEMATOLOGY (2002)
Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma
A Rambaldi et al.
BLOOD (2002)
Lack of correlation between numbers of circulating t(14;18)-positive cells and response to first-line treatment in follicular lymphoma
CMPW Mandigers et al.
BLOOD (2001)
A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients
M Ladetto et al.
EXPERIMENTAL HEMATOLOGY (2001)
分享论文
